Zai Lab Ltd. - Multiplikator Forward P/S ZLAB

Zai Lab Limited (ZLAB) dominates the segment of adapting Western innovations for China, leveraging its patents and expertise in local regulations. The business model is based on the exclusive right to sell foreign pharmaceuticals, despite government price controls. Revenue growth is driven by the Vyvgart launch and access to state insurance. The projected P/S multiple helps assess market value relative to forecasts, while the 6.60 indicator reflects the status of the current valuation.

Zai Lab Limited (ZLAB) is scaling its presence in the Chinese market through strategic licensing agreements and the acquisition of R&D centers, establishing a foundation for long-term revenue growth. By analyzing the forward P/S ratio, an investor assesses the current share price relative to expected revenue, which helps identify liquidity inflows and determine the extent of the asset's overvaluation within the context of the fundamental expectations of pension funds.